Literature DB >> 31476516

Allergic eye disease in children and adolescents seeking eye care in India: Electronic medical records driven big data analytics report II.

Anthony Vipin Das1, Pragnya R Donthineni2, Gumpili Sai Prashanthi3, Sayan Basu4.   

Abstract

PURPOSE: To describe the demographics, clinical presentation and risk-factors of allergic eye disease (AED) in children and adolescents presenting to a multi-tier ophthalmology hospital network in India.
METHODS: This was a hospital-based cross-sectional study of 259,969 new patients (≤21 years of age) presenting between 2010 and 2018. Patients with a clinical diagnosis of AED were considered as cases. Data were collected using an electronic medical record system. Multiple logistic regression with odds ratios (OR) was performed to identify the high risk-factors of AED.
RESULTS: Overall, 26,309 (10.1%) children and adolescents were diagnosed with AED. The prevalence of AED was 0.3%, 6.6%, 18.3%, 15.8%, 8.1%, and 4.9% in infancy (<1 years), toddlerhood (1-2 years), early childhood (3-5 years), middle childhood (6-11 years), early adolescence (12-18 years) and late adolescence (18-21 years), respectively. Most patients with AED presented in spring and summer. Palpebral vernal keratoconjunctivitis was the commonest clinical form, seen in 42.8% of eyes. Corneal scarring, keratoconus, limbal stem cell deficiency and shield ulcers were seen in 2.4%, 1.4%, 0.4% and 0.3% of eyes, respectively. Male sex (OR 2.05); early and middle childhood age groups (OR 66.6; 59.1); higher socio-economic class (OR 1.46) and history of systemic allergy (OR 3.74) were identified as high-risk factors of AED.
CONCLUSION: About a tenth of the children and adolescents seeking eye care in India are affected by AED, which commonly affects boys with atopy, from middle to higher income families during their early to middle childhood and shows a self-limiting trend by late adolescence.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Allergic conjunctivitis; Allergic eye disease; Big data; Electronic medical records; Epidemiology; Vernal keratoconjunctivitis

Mesh:

Year:  2019        PMID: 31476516     DOI: 10.1016/j.jtos.2019.08.011

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  6 in total

1.  Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial.

Authors:  Minjie Chen; Bilian Ke; Jun Zou; Lan Gong; Yan Wang; Chaoran Zhang; Jianjiang Xu; Anji Wei; Jiaxu Hong
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

2.  Demography and Clinical Features of Chalazion Among Patients Seen at a Multi-Tier Eye Care Network in India: An Electronic Medical Records Driven Big Data Analysis Report.

Authors:  Anthony Vipin Das; Tarjani Vivek Dave
Journal:  Clin Ophthalmol       Date:  2020-07-28

3.  Managing ocular allergy in the time of COVID-19.

Authors:  Andrea Leonardi; Jean L Fauquert; Serge Doan; Luis Delgado; Nicolas Andant; Ludger Klimek; Banu Bozkurt
Journal:  Allergy       Date:  2020-05-25       Impact factor: 13.146

4.  People to policy: The promise and challenges of big data for India.

Authors:  Anthony Vipin Das
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

5.  Environmental and Air Pollution Factors Affecting Allergic Eye Disease in Children and Adolescents in India.

Authors:  Anthony Vipin Das; Sayan Basu
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

6.  Ophthatome™: an integrated knowledgebase of ophthalmic diseases for translating vision research into the clinic.

Authors:  Praveen Raj; Sushma Tejwani; Dandayudhapani Sudha; B Muthu Narayanan; Chandrasekar Thangapandi; Sankar Das; J Somasekar; Susmithasane Mangalapudi; Durgesh Kumar; Narendra Pindipappanahalli; Rohit Shetty; Arkasubhra Ghosh; Govindasamy Kumaramanickavel; Amitabha Chaudhuri; Nagasamy Soumittra
Journal:  BMC Ophthalmol       Date:  2020-11-10       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.